Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Emcure’s Cut-Price Eribulin Dull Halaven In India?

Executive Summary

Emcure has launched a generic version of Eisai’s cancer drug Halaven on the Indian market at a sharp 40% discount to the innovator product, and hopes to expand patient access significantly.

You may also be interested in...



Do Not Be So Quick To Blame Microbes On The Lab, The US FDA Warns Emcure

Emcure's Hinjwadi, India, plant should have investigated other more likely sources of contamination more thoroughly, the FDA says.

India’s Emcure Launches First Generic of Eisai's Halaven, Changing Pricing Scenario

Indian drug company Emcure says it is launching the first generic version of Japanese drugmaker Eisai's Halaven which targets metastatic breast cancer and will undercut the branded drug’s price in the country by nearly half.

How Eisai Hopes To Expand In India

Japan's Eisai appears set for a significant step up in product introductions in India. Improving access to these medicines for patients in the largely self-pay market is at the fulcrum of its strategy, Dr Sanjit Singh Lamba, managing director of Eisai Pharmaceuticals India Pvt Ltd, tells Scrip. Newer options like a second brand approach may also be evaluated for certain new products to expand access and availability across the country.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125018

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel